Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Oxfendazole in Healthy Volunteers
NCT02234570Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Nov 2014
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of oxfendazole in neurocysticercosis (NCC), sponsored by National Institute of Allergy and Infectious Diseases. Started Nov 2014; status: completed.
02
Drugs
oxfendazole
03
Conditions
neurocysticercosis (NCC)
Beyond the preview
Go deeper on NCT02234570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02234570.